John David Finley sold $6,818 of PALI
CEO, CFO at PALISADE BIO, INC.. 3,896 shares at an average of $1.75, traded Feb 12, 2026, filed Feb 13, 2026.
Score components
- +25RoleCEO
- 0Trade size$7k at market
- +5Share of holdings soldSold 12% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.1%, 3m +5.8%, 6m +23.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-006831, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | MOption exercise Common Stock | +13,333 | - | - | 31,249 | Feb 13, 2026 |
| Feb 12, 2026 | SOpen-market sale Common Stock | -3,896 | $1.75 | $6,818 | 27,353 | Feb 13, 2026 |
| Feb 11, 2026 | MOption exercise Restricted Stock Unitsderivative | -13,333 | $0.00 | $0 | 26,667 | Feb 13, 2026 |
Related signals
Other insiders at PALISADE BIO, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | PALIbuy PALISADE BIO, INC. | Donald Allen Williams director | $29k 20,000 shares | +1% | |
| 36Weak | PALIbuy PALISADE BIO, INC. | Robert Baltera Jr. director | $89k 45,000 shares | +11% | |
| 37Weak | PALIbuy PALISADE BIO, INC. | Robert Baltera Jr. director | $102k 50,000 shares | +14% | |
| 42Moderate | PALISADE BIO, INC. | John David Finley CEO, CFO | $303k 146,798 shares | -40% | |
| 28Weak | PALISADE BIO, INC. | Mitchell Lawrence Jones Chief Medical Officer | $107k 51,880 shares | -36% | |
| 29Weak | PALIbuy PALISADE BIO, INC. | Robert Baltera Jr. director | $59k 30,000 shares | +9% | |
| 13Weak | PALISADE BIO, INC. | Mitchell Lawrence Jones Chief Medical Officer | $3,481 1,989 shares | -13% | |
| 38Weak | PALIbuy PALISADE BIO, INC. | Donald Allen Williams director | $8,356 5,000 shares | +87% | |
| 29Weak | PALIbuy PALISADE BIO, INC. | Donald Allen Williams director | $9,400 5,000 shares | +687% | |
| 39Weak | PALISADE BIO, INC. | Donald Allen Williams director | $4,863 1,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.